MAIA Biotechnology, Inc. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent
MAIA Biotechnology, Inc. (MAIA) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent of -$19.61 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent · last filed 2026-03-23
- MAIA Biotechnology, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-12-31 was -$19.39K.
- MAIA Biotechnology, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-09-30 was -$807.00, a 107.70% decline year-over-year.
- MAIA Biotechnology, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-06-30 was $8.13K, a 3.29% increase year-over-year.
- MAIA Biotechnology, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-03-31 was -$7.54K.
- MAIA Biotechnology, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2025 was -$19.61K.
- MAIA Biotechnology, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2024 was -$14.36K.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$19.39K derived: 10-K 12 month − 3 quarters · filed 2026-03-23 | -$20.20K derived: sum of 2 quarters · filed 2026-03-23 | -$12.07K derived: sum of 3 quarters · filed 2026-03-23 | -$19.61K 10-K · filed 2026-03-23 |
| 2025-09-30 | -$807.00 10-Q · filed 2025-11-07 | $7.32K derived: sum of 2 quarters · filed 2025-11-07 | -$220.00 derived: sum of 3 quarters · filed 2025-11-07 | |
| 2025-06-30 | $8.13K 10-Q · filed 2025-11-07 | $587.00 derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2025-03-31 | -$7.54K 10-Q · filed 2025-11-07 | |||
| 2024-12-31 | -$14.36K 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $10.48K 10-Q · filed 2025-11-07 | $18.34K derived: sum of 2 quarters · filed 2025-11-07 | $4.56K derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $7.87K 10-Q · filed 2025-11-07 | -$5.92K derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | -$13.79K 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |